CD6-depleted allogeneic bone marrow transplantation for acute leukemia in first complete remission

Robert J. Soiffer, Diane Fairclough, Michael Robertson, Edwin Alyea, Kenneth Anderson, Arnold Freedman, Lini Bartlett-Pandite, David Fisher, Robert L. Schlossman, Richard Stone, Christine Murray, Andrea Freeman, Karen Marcus, Peter Mauch, Lee Nadler, Jerome Ritz

Research output: Contribution to journalArticle

72 Scopus citations

Abstract

The appropriate timing of bone marrow transplantation (BMT) for adults with acute myelogenous leukemia (AML) and acute lymphoblastic leukemia (ALL) is controversial. Although allogeneic transplantation results in a lower risk of disease recurrence than intensive chemotherapy alone, overall outcome following BMT may not be improved due to the higher incidence of therapy- related fatal complications, frequently as a result of the development of graft-versus-host disease (GVHD). Selective T-cell depletion of donor marrow can reduce the incidence of GVHD and thereby limit transplant-related toxicity. Herein we report the risk of GVHD, incidence of transplant related mortality (TRM), likelihood of disease relapse, and overall survival in adult patients undergoing BMT with CD6 depleted allogeneic marrow for acute leukemia in first remission. Forty-one consecutive allogeneic transplants were performed on patients with acute leukemia and high-risk features (28 AML, 13 ALL) using T12 monoclonal antibody and complement to remove CD6+ T cells from donor marrow. No pre- or posttransplant immune suppressive medications for GVHD prophylaxis were administered. The actuarial estimated risk of grade 2 to 4 acute GVHD was 15% in patients receiving HLA identical grafts. Chronic GVHD developed in five patients. The estimated risk of TRM for patients in first complete remission was 5% at Day +100 and 16% at 2 years. Fatalities attributable to infection with cytomegalovirus or Epstein- Barr virus occurred in only three patients. Estimated probabilities of relapse, overall survival, and event-free survival at 4 years were 25%, 71%, and 63%, respectively. No significant differences in GVHD, TRM, relapse rate, or survival was observed for patients with AML compared with those with ALL. Allogeneic transplantation with CD6 depleted bone marrow is effective in consolidating remissions of high-risk patients with acute leukemia in first remission without excessive toxicity.

Original languageEnglish (US)
Pages (from-to)3039-3047
Number of pages9
JournalBlood
Volume89
Issue number8
StatePublished - Apr 15 1997
Externally publishedYes

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology

Fingerprint Dive into the research topics of 'CD6-depleted allogeneic bone marrow transplantation for acute leukemia in first complete remission'. Together they form a unique fingerprint.

  • Cite this

    Soiffer, R. J., Fairclough, D., Robertson, M., Alyea, E., Anderson, K., Freedman, A., Bartlett-Pandite, L., Fisher, D., Schlossman, R. L., Stone, R., Murray, C., Freeman, A., Marcus, K., Mauch, P., Nadler, L., & Ritz, J. (1997). CD6-depleted allogeneic bone marrow transplantation for acute leukemia in first complete remission. Blood, 89(8), 3039-3047.